AI News AI资讯 5d ago Updated 5d ago 更新于 5天前 40

Krypton Star Evening News: Tencent and Alibaba Invest in BCI Developer Jieti Medical; Fliggy Reports 6x Surge in Dragon Boat Festival Inbound Bookings; Futures Market Turnover Up 40.13% 氪星晚报 |腾讯、阿里等入股脑机接口研发商阶梯医疗;飞猪:端午假期入境游预订量同比增长超6倍;1—5月全国期货市场累计成交额同比增长40.13%

Major tech companies suddenly collectively invested in an obscure medical firm with a mere 1 million yuan in registered capital. Step Medical, a brain-computer interface (BCI) startup founded only in 2021, saw two new shareholders emerge through business registration changes: Hangzhou Haoyue (affiliated with Alibaba) and Shanghai Qishan (affiliated with Tencent). The news itself seems unremarkable, but the strategic intent behind it is like a stone thrown into deep water—ripples spread outward, 大厂们突然集体潜入一家注册资本仅100万元、名不见经传的医疗公司。阶梯医疗,这家2021年才成立的脑机接口初创企业,在工商变更中迎来两位新股东:阿里的杭州灏月和腾讯的上海启善。消息本身平平无奇,但背后的战略意图却像一枚投入深水的石子,涟漪荡开,折射出中国科技巨头在AI前沿领域焦躁而迫切的布局心态。

60
Hot 热度
55
Quality 质量
55
Impact 影响力

Analysis 深度分析

Major tech companies suddenly collectively invested in an obscure medical firm with a mere 1 million yuan in registered capital. Step Medical, a brain-computer interface (BCI) startup founded only in 2021, saw two new shareholders emerge through business registration changes: Hangzhou Haoyue (affiliated with Alibaba) and Shanghai Qishan (affiliated with Tencent). The news itself seems unremarkable, but the strategic intent behind it is like a stone thrown into deep water—ripples spread outward, reflecting the anxious and urgent deployment mindset of Chinese tech giants in the cutting-edge field of AI.

This is not a simple financial investment. Judging from the capital contribution and equity dilution (with registered capital increasing from 1 million to about 3 million yuan), the stakes acquired by Tencent and Alibaba are extremely limited—more akin to a "boarding pass" they must seize. What they are betting on is less the current technological maturity of Step Medical and more the "admission ticket" to the ultimate race of brain-computer interfaces. When AI large models face homogenization and intense competition at the application level, capital must seek a harder narrative and a more defensible moat for the "post-AI era" in advance. Brain-computer interfaces, a field once dramatized by science fiction and hyped by Elon Musk, have become the ultimate battlefield in the eyes of giants—a "high-risk, high-barrier, once-breakthrough-then-disruptive" frontier—due to its interdisciplinary complexity and potential to penetrate underlying life sciences. This is both a defensive deployment and a fear-driven bet on the future computing paradigm evolving from "human-machine interaction" to "human-machine integration."

However, between the vast ocean of technological potential and the stark realities of commerce, there always lies a turbulent river. Step Medical's website describes its business as "implantable brain-computer interfaces"—a field that requires traversing extremely long clinical verification cycles, navigating high ethical risks, and overcoming significant technical barriers. Can the capital injection from these giants accelerate its journey from the lab to the operating room? Perhaps not entirely. Capital can accelerate applications at the application layer but struggles to speed up the maturation of disruptive foundational technologies. This funding is more likely to sustain its early-stage R&D and team building, while true breakthroughs still demand long and solitary scientific exploration. The giants' "rush to invest" demonstrates respect for frontier technology but also reveals a typical internet-era anxiety: fearing to miss any potential singularity, they would rather cast a wide net. This mindset is no different from the logic that drove investments in the metaverse five years ago or VR a decade ago.

Turning our gaze from neural interfaces back to the more pressing AI competition at hand: Maoyan Entertainment’s integration into WeChat's AI Agent ecosystem, offering end-to-end intelligent services from film selection to ticket purchases, marks that the AI deployment of large companies has accelerated from the model and platform layers down to the finest capillaries of consumer scenarios. AI Agents are no longer a vague concept but have become digital assistants in your pockets that can help you select seats and make payments. This is pragmatic, yet intensely competitive. When all companies strive to become "the AI butler who understands you best," the competition may no longer be about who has the most advanced technology, but whose ecosystem is more closed-loop, whose data is richer, and whose user habits are harder to sway. This is an arms race at the application level—exciting but likely to quickly become a red ocean.

Meanwhile, another set of data outlines the contours of hard power: China’s share of the global LNG carrier market has exceeded 30%, with orders extending beyond 2030. This stands in stark contrast to the "distant future" of brain-computer interfaces. It represents solid footsteps of manufacturing achieving "positioning" or even "leadership" in specific niche fields. Its success does not rely on a genius concept but stems from continuous technological iteration, cost control, and supply chain synergy. Similarly, the significant growth in futures market turnover reflects the increasing activity of the real economy using financial tools to manage risk. These "weighty" indicators may better capture the true pulse of the economic body than a few funding announcements from star companies.

The current picture is fragmented: On one side, giants are paying expensive "option premiums" for a distant neural future; on the other, consumer-level AI services are optimizing experiences at the finest margins. On one side, hardcore manufacturing is building barriers in deep waters; on the other, capital markets are voting with real money for the latest technological narrative. This fragmentation itself might be the true state of technological evolution—while chasing "the next" grand concept, one must not neglect the cultivation of "every present link." However, as giants extend their tentacles toward the cerebral cortex, we perhaps need a bit more clarity: the romantic narratives of technology must ultimately be validated by hard clinical data, strong ethical constraints, and genuine market demands. Otherwise, even the cleverest "brain-computer interface" might only connect to capital illusions born of wishful thinking.

大厂们突然集体潜入一家注册资本仅100万元、名不见经传的医疗公司。阶梯医疗,这家2021年才成立的脑机接口初创企业,在工商变更中迎来两位新股东:阿里的杭州灏月和腾讯的上海启善。消息本身平平无奇,但背后的战略意图却像一枚投入深水的石子,涟漪荡开,折射出中国科技巨头在AI前沿领域焦躁而迫切的布局心态。

这不是一次简单的财务投资。从出资额和股权稀释看(注册资本从100万增至约300万),腾讯阿里所获份额极其有限,更像是一个需要抢占的“船票”。它们押注的,与其说是阶梯医疗当前的技术成熟度,不如说是脑机接口这个终极赛道的“可能性入场券”。当AI大模型在应用层陷入同质化内卷时,资本必须提前为“后AI时代”寻找更硬核的叙事和护城河。脑机接口,这个曾被科幻渲染、被马斯克高调带货的领域,正因其跨学科的复杂性和对底层生命科学的渗透潜力,成为巨头眼中“高风险、高门槛、一旦突破即颠覆”的终极战场。这是一种防御性布局,也是一种对未来计算范式从“人机交互”迈向“人机融合”的恐惧性押注。

然而,技术的星辰大海与商业的骨感现实之间,永远隔着一条湍急的河流。阶梯医疗官网描述其业务为“植入式脑机接口”,这是一个需要跨越极长临床验证周期、极高伦理风险和极高技术壁垒的领域。大厂的注资,能加速其从实验室走向手术室吗?恐怕未必。资本能催熟应用层的应用,却很难催熟一项颠覆性的基础技术。这笔钱更可能用于维持其早期研发和团队搭建,真正的突破仍需漫长而孤独的科学探索。巨头的“一拥而上”,既彰显了对前沿技术的尊重,也透露出一种典型的互联网式焦虑:害怕错过任何一个可能的奇点,于是宁可广泛撒网。这种心态,与五年前追逐元宇宙、十年前追逐VR的逻辑并无二致。

视线从神经接口拉回当下更紧迫的AI竞赛。猫眼娱乐接入微信AI Agent生态,提供从选片到购票的全链路智能服务,这标志着大公司的AI布局已从模型层、平台层,加速下沉到最细微的消费场景毛细血管。AI Agent不再是一个模糊的概念,而是变成了你口袋里能帮你选座、付钱的数字助手。这很务实,但也很“卷”。当所有公司都在争做“最懂你的AI管家”时,比拼的可能不再是技术多先进,而是谁的生态更闭环、谁的数据更丰富、谁的用户习惯更难被撬动。这是一种应用层面的军备竞赛,热闹,但可能迅速红海化。

与此同时,另一组数据则勾勒出硬实力的轮廓。中国在全球LNG船市场份额突破30%,订单排到2030年后,这与脑机接口的“遥远未来”形成鲜明对比。这是制造业在特定细分领域实现“卡位”甚至“领先”的扎实脚印。它的成功不依赖于某个天才概念,而源于持续的技术迭代、成本控制和产业链协同。同样,期货市场成交额的大幅增长,反映的是实体经济利用金融工具管理风险的活跃度在提升。这些“笨重”的指标,或许比几则明星公司的融资消息,更能体现经济肌体的真实脉搏。

当前的图景是分裂的:一边是巨头为遥远的神经未来支付昂贵的“期权费”,一边是消费级AI服务在毫厘之间优化体验;一边是硬核制造业在深水区构筑壁垒,一边是资本市场用真金白银投票给最新的技术叙事。这种分裂本身或许就是科技产业演进的真实状态——在追逐“下一个”伟大概念的同时,绝不能放松对“当下”每一个环节的深耕。只是,当巨头们纷纷将触角探向大脑皮层时,我们或许该多一分清醒:技术的浪漫叙事终究要靠临床的硬数据、伦理的强约束和市场的真需求来验证。否则,再聪明的“脑机”,也可能连接的只是一厢情愿的资本幻梦。

Disclaimer: The above content is generated by AI and is for reference only. 免责声明:以上内容由 AI 生成,仅供参考。

Agent Agent 部署 部署
Share: 分享到: